Related Experiment Video
Updated: May 12, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Biological therapies for rheumatoid arthritis: progress to date
Gaurav Malviya1, Simonetta Salemi, Bruno Laganà
1Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, The Netherlands.
Abstract:
Biologic drugs for the management of rheumatoid arthritis (RA) have revolutionized the therapeutic armamentarium with the development of several novel monoclonal antibodies, which include murine, chimeric, humanized, fully human antibodies and fusion proteins. These biologics bind to their targets with high affinity and specificity. Since 1998, nine different biologics have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA, and several others are in different stages of clinical trials. This field is in continuous evolution and new biologics are tested every year. Therefore a precise analysis is required in order to have a detailed and updated state of the art of this field. In this review, our main aim is to analyse all available biological therapies that are FDA and EMA approved for the treatment of RA and also those that are in clinical trials for the management of RA patients.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
The JAK-STAT Signaling Pathway
Microorganisms in Medicine and Therapeutics
Mesenchymal Stem Cells
Rheumatic Heart Disease III: Medical Management